American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates
16 May 2014 | By Pfizer
Public health initiative aims to increase unacceptably low adult vaccination rates...
List view / Grid view
News
Phase 3a data from largest trial with liraglutide 3 mg demonstrated significantly greater weight loss versus placebo for adults with obesity
16 May 2014 | By Novo Nordisk
Results from the SCALE™ Obesity and Pre-diabetes phase 3a trial will be presented on 16 May, 2014 for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists...
FDA issues Complete Response Letter for RLX030 for acute heart failure
16 May 2014 | By Novartis
Novartis announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License Application for RLX030...
Abbott expands Latin American presence and branded generics portfolio with acquisition of CFR Pharmaceuticals
16 May 2014 | By Abbott
Abbott enhances its position in fast-growing Latin American market, more than doubling its branded generics pharmaceutical sales and presence in the region...
Enigma Diagnostics and China’s ICDC announce collaboration to develop MDx infectious disease assays on Enigma ML system for use at point-of-care
15 May 2014 | By Enigma Diagnostics
Enigma Diagnostics Ltd announced a collaboration agreement with China’s National Institute for Communicable Disease Control and Prevention, China Center for Disease Control and Prevention...
Novartis settles patent litigation on Gleevec® (imatinib mesylate) with Sun Pharma subsidiary
15 May 2014 | By Novartis
Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec®...
AstraZeneca to demonstrate the strength and rapid acceleration of its oncology pipeline at ASCO 2014
15 May 2014 | By AstraZeneca
New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline...
New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer
15 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
Roche to present new data on 27 different medicines at ASCO
14 May 2014 | By Roche
Roche announced that new data on nine approved and 18 investigational medicines will be presented during the 50th American Society of Clinical Oncology Annual Meeting...
Transatlantic Taskforce on Antimicrobial Resistance reports progress and outcomes of 17 recommendations
14 May 2014 | By The European Medicines Agency
The European Commission and the US Department of Health and Human Services have published a progress report of the Transatlantic Taskforce on Antimicrobial Resistance...
Supplemental New Drug Applications for once-monthly long-acting therapy INVEGA® SUSTENNA® submitted to the U.S. FDA for the treatment of schizoaffective disorder
14 May 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc., announced the submission of supplemental New Drug Applications for once-monthly atypical long-acting antipsychotic INVEGA® SUSTENNA® (paliperidone palmitate) to the U.S. Food and Drug Administration...
MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial
14 May 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation...
Merck signs sale agreement with Santen for Merck’s ophthalmology products in Japan and key markets in Europe and Asia Pacific
13 May 2014 | By Merck
Merck announced that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck’s ophthalmology products...
GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome
13 May 2014 | By GlaxoSmithKline
GlaxoSmithKline announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome...
Statement regarding Pfizer announcement
13 May 2014 | By Astrazeneca
The Board of AstraZeneca PLC notes the announcement made by Pfizer Inc. earlier...
